S

anofi and Regeneron Pharmaceuticals won a notable victory on Thursday when a federal appeals court reversed a ban on the sale of their pricey cholesterol medicine and ordered a new trial to decide a bitter patent dispute with Amgen, their only rival in a potentially lucrative market.

The appeals court permanently removed an injunction that had actually been suspended several months ago. It would have prevented Sanofi and Regeneron from marketing Praluent, a newer type of cholesterol medicine. The injunction was initially granted by a lower court after a jury last year found their drug infringed on patents held by Amgen, which sells a competing treatment called Repatha.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy